Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
Molecular Weight:
219.28
Purity:
98
CAS Number:
[141206-42-0]
Formula:
C10H21NO4
Target:
Glucosylceramide Synthase (GCS)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted